Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TREX reveals proteins that bind to specific RNA regions in living cells.
Dodel M, Guiducci G, Dermit M, Krishnamurthy S, Alard EL, Capraro F, Rekad Z, Stojic L, Mardakheh FK. Dodel M, et al. Nat Methods. 2024 Mar;21(3):423-434. doi: 10.1038/s41592-024-02181-1. Epub 2024 Feb 19. Nat Methods. 2024. PMID: 38374261 Free PMC article.
Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study.
Hupé M, Streichenberger A, Wils P, Arab N, Serrero M, Amiot A, Bozon A, Vuitton L, Fumery M, Altwegg R, Nachury M, Hébuterne X, Yzet C, Coban D, Dodel M, Bazoge M, Pereira B, Buisson A. Hupé M, et al. Among authors: dodel m. Dig Liver Dis. 2024 Jan 27:S1590-8658(24)00200-7. doi: 10.1016/j.dld.2024.01.181. Online ahead of print. Dig Liver Dis. 2024. PMID: 38281870
Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study.
Buisson A, Nachury M, Bazoge M, Yzet C, Wils P, Dodel M, Coban D, Pereira B, Fumery M. Buisson A, et al. Among authors: dodel m. Aliment Pharmacol Ther. 2024 Feb;59(4):526-534. doi: 10.1111/apt.17822. Epub 2023 Nov 30. Aliment Pharmacol Ther. 2024. PMID: 38037279 Clinical Trial.
Tofacitinib for Patients with Anti-TNF Refractory Ulcerative Proctitis: A Multicentre Cohort Study from the GETAID.
Uzzan M, Nachury M, Nuzzo A, Amiot A, Caron B, Benezech A, Buisson A, Bouguen G, Le Berre C, Reenaers C, Le Cosquer G, Savoye G, Charkaoui M, Vidon M, Guillo L, Fumery M, Peyrin-Biroulet L, Kirchgesner J, Bouhnik Y; GETAID TOFA-PRO study group. Uzzan M, et al. J Crohns Colitis. 2024 Mar 1;18(3):424-430. doi: 10.1093/ecco-jcc/jjad169. J Crohns Colitis. 2024. PMID: 37796025 Free article.
An mRNA processing pathway suppresses metastasis by governing translational control from the nucleus.
Navickas A, Asgharian H, Winkler J, Fish L, Garcia K, Markett D, Dodel M, Culbertson B, Miglani S, Joshi T, Yin K, Nguyen P, Zhang S, Stevers N, Hwang HW, Mardakheh F, Goga A, Goodarzi H. Navickas A, et al. Among authors: dodel m. Nat Cell Biol. 2023 Jun;25(6):892-903. doi: 10.1038/s41556-023-01141-9. Epub 2023 May 8. Nat Cell Biol. 2023. PMID: 37156909 Free PMC article.
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2023 Mar;21(3):771-788.e10. doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22. Clin Gastroenterol Hepatol. 2023. PMID: 36152897 Free article.
Role of adherent and invasive Escherichia coli in Crohn's disease: lessons from the postoperative recurrence model.
Buisson A, Sokol H, Hammoudi N, Nancey S, Treton X, Nachury M, Fumery M, Hébuterne X, Rodrigues M, Hugot JP, Boschetti G, Stefanescu C, Wils P, Seksik P, Le Bourhis L, Bezault M, Sauvanet P, Pereira B, Allez M, Barnich N; Remind study group. Buisson A, et al. Gut. 2023 Jan;72(1):39-48. doi: 10.1136/gutjnl-2021-325971. Epub 2022 Mar 31. Gut. 2023. PMID: 35361684 Clinical Trial.
37 results